pharmaphorum

SEPTEMBER 22, 2022

We chart the unusual metamorphosis of pharma marketing, from patent pages to personalised apps. IQVIA’s Elizabeth Murray, Steven Ferguson, Steve How, and Martin Fox explain the importance of understanding the market landscape and aligning commercial and engagement strategies with the needs of consumers. Frontiers Health 2022.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

MAY 17, 2021

Many life sciences companies have begun 2021 by reviewing how they respond to the longer-term impact of this change – and its impact on sales forces is a major topic. Sales force adoption (48% of respondents) was deemed a key success factor for omnichannel engagement with HCPs in the ‘next normal’ (IQVIA survey, March 2021).

Communication 72

Communication 72

Pharmaceutical Technology

JULY 12, 2022

Despite the market size for B-cell non-Hodgkin’s lymphoma (NHL) being at least five times that of ALL, NHL has a smaller pipeline of cell therapies. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.

FDA 52

FDA 52

Omnicell

JANUARY 10, 2023

By the Numbers: Our Interns in 2021 29 teams supported at Omnicell, including software engineering, finance, supply chain, marketing, intelligence, and more 42 interns from 32 U.S. Associate Technical Sales Engineer, and former Omnicell intern Q: What's something that surprised you about Omnicell? A: "How friendly the people are!

Omnicell 98

Omnicell Insurance Communication 98

pharmaphorum

NOVEMBER 2, 2020

Digital therapeutics are gaining momentum worldwide and offer developers, including pharma, both a huge opportunity and a stimulating market access challenge, say Olaf Schoeman and Emanuele Arcà. Thriving in COVID-19 with flexible marketing strategies. Pharma sales is set to change forever.

Pharmaceutical Companies 58

Pharmaceutical Companies Pharmaceutical Companies 58

pharmaphorum

DECEMBER 7, 2022

Pricing and market access in France operate on a dual system, under which health technology assessments (HTAs) are conducted separately from pricing negotiations. Source: CT assessments [Haute Autorité de Santé website]; ANSM [Agence Nationale de Sécurité du Médicament et des Produits de Santé]; CRA analysis). Source: CRA analysis).

104

104

pharmaphorum

APRIL 1, 2022

However, while this dramatic shake-up of the UK Market Access environment aims to improve care for patients and providers for life science companies, this unfamiliar territory presents both opportunities and challenges. The post ICSs – an opportunity to improve Patient & Market Access at a local level appeared first on.

98

98

pharmaphorum

SEPTEMBER 17, 2020

In this issue we hear from a variety of KOLs who are leading pharma comms into a new, digital era to get their views on how pharma can best adapt for the post-COVID world. OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharma.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies 52

Omnicell

FEBRUARY 16, 2023

Omnicell Specialty Pharmacy Services helped Temple gain access to Limited Distribution Drugs, accelerated accreditation, provided staffing, and delivered a set of proven policies and procedures that accelerated the organization’s speed-to-market.

Specialty Pharmacies 52

Specialty Pharmacies Omnicell Hospitals Compounding 52

pharmaphorum

JUNE 20, 2022

Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights activities within the orphan drug market and forecasts what the future of the industry holds based on data. Revising legislation.

FDA 52

FDA 52

Pharma Marketing Network

JULY 21, 2021

The summit consisted of three panel discussions: “Coordinated CX: Moving Beyond Campaign Management,” “Digital Customer Experience and Analytics,” and “The Engagement Matrix: A Holistic View of CX.” Lars Merk , Senior Global Marketing Director at AstraZeneca , spoke to the connection between customer centricity and the evolution of CX. “We

Communication 52

Communication 52

Fuld

JANUARY 21, 2020

For more than 40 years, Fuld + Company has partnered with its clients to deliver strategic insights, guidance and industry analysis that support executive decision-making. As company-leaders plan for the year ahead, they should consider why a 3 rd party on-site strategic intelligence resource might be good for business.

Process Improvement 78

Process Improvement Documentation 78

Pharma Marketing Network

JULY 21, 2021

The summit consisted of three panel discussions: “Coordinated CX: Moving Beyond Campaign Management,” “Digital Customer Experience and Analytics,” and “The Engagement Matrix: A Holistic View of CX.” Lars Merk , Senior Global Marketing Director at AstraZeneca , spoke to the connection between customer centricity and the evolution of CX. “We

Communication 52

Communication 52

pharmaphorum

DECEMBER 14, 2020

As this issue’s title suggests, patient centricity is about more than just talking points and marketing strategies – it requires companies to truly listen to, engage with and partner with the patients they serve, and in putting this month’s Deep Dive together it’s been great to see that so many pharma firms are now taking this to heart.

Pharmaceutical Companies 75

Pharmaceutical Companies Pharmaceutical Companies FDA 75

pharmaphorum

JANUARY 24, 2023

As the analysis in our graphic shows, the only exception where engagement volumes have recovered is the US. A longer historic view of biotech funding, however, reverses the picture: 2020 and 2021 were not normal years. Venture capital poured into the pandemic biotech markets and not every investment was good quality.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Vaccines 98

pharmaphorum

FEBRUARY 26, 2021

Emma Sutcliffe from NexGen Healthcare Communications looks at how patient insights can bring the invisible challenges of living with a rare condition into plain view. Focus on Rare: the invisible burden of rare diseases. Digitalising drug discovery.

Vaccines 58

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 58

pharmaphorum

JANUARY 22, 2021

In this article, we focus in particular on how COVID-19 may be changing prescribing decisions using market research and claims data. Analysis of prescribing changes. Source: CRA market research (conducted June 2020). Source: CRA claims data analysis (using claims through June 2020). Changes in Prescribing by Specialty.

Specialty Pharmacies 104

Specialty Pharmacies Pharmaceutical Companies Pharmaceutical Companies Vaccines 104

Pharmaceutical Technology

JULY 6, 2022

Business optimism improved in June 2022 compared to May 2022, even amid concerns over rising costs and slowing demand, revealed an analysis of an ongoing poll by Verdict. Analysis of the poll responses recorded in June 2022 shows that optimism regarding future growth prospects increased by five percentage points to 63% from 58% in May 2022.

52

52

pharmaphorum

FEBRUARY 11, 2022

“It’s our representation of tracking the deidentified, which is important from a privacy and compliance point of view,” Sun says. “It For example, Komodo has modules in their solutions suite allowing users to view the diagnostic journey of a patient who’s had a confirmatory diagnosis. “We ” About the interviewee.

104

104

pharmaphorum

APRIL 16, 2021

The launch environment was directly impacted by the COVID-19 pandemic, which hit two key drivers of launch uptake particularly hard: the dynamic market, i.e. new and switch prescriptions, and face-to-face interactive engagement with healthcare professionals. Here we assess the launches of New Active Substances (NAS) only.

Pharmaceutical Companies 95

Pharmaceutical Companies Pharmaceutical Companies Documentation Vaccines 95

Pharmaceutical Technology

SEPTEMBER 6, 2022

Verdict has been conducting the poll to study the trends in business optimism during COVID-19 as reflected by the views of companies on their future growth prospects amid the pandemic. The analysis is based on 321 responses received from the readers of Verdict network sites between 01 August and 31 August 2022.

52

52

pharmaphorum

MAY 14, 2021

Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage. This article appears in our digital magazine, Deep Dive: Market Access 2021. It’s important to remember that the UK market represents only 2.5% This additional effort could lead to poorer patient access. “It

Documentation 58

Documentation Pharmaceutical Companies Pharmaceutical Companies 58

Omnicell

JANUARY 10, 2023

The minimum discounts that Medicare could demand vary based on the age of the drug: 25% for drugs on the market for more than nine years; 35% for drugs on the market for more than 12 years; and 60% for drugs on the market for more than 16 years. Disclaimer The views and opinions expressed in this blog are those of the authors.

Hospitals 52

Hospitals Omnicell Pharmaceutical Companies Pharmaceutical Companies 52

Omnicell

JANUARY 10, 2023

The law also requires manufacturers to pay rebates on Medicare drugs reimbursed under Part B or D when the average manufacturer price (AMP) for a particular drug rises faster than inflation, with the rebate calculated based on the difference between the drug maker’s price and the inflation rate for all sales of that drug to Medicare.

Omnicell 52

Omnicell Insurance 52

ISPE

JULY 6, 2023

Should issues or events arise over time, a root cause analysis (RCA) would be used to identify what happened and provide recommendations on mitigating such occurrences in the future. The process is dynamic with a built-in feedback mechanism. A precursor to measuring any risk associated with CM is the development of a risk profile.

Insurance 52

Insurance Documentation Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

OCTOBER 7, 2022

Verdict has been conducting the poll to study the trends in business optimism during COVID-19 as reflected by the views of companies on their future growth prospects amid the pandemic. The analysis is based on 373 responses received from the readers of Verdict network sites between 01 September and 30 September 2022. from 103.0

52

52

Omnicell

JANUARY 10, 2023

Justice Elena Kagan observed: “The provision says, if you have survey data, you do one thing” — pay acquisition costs — “and if you don’t have survey data, you do a different thing” — pay the average sales price plus 6 percent.

Hospitals 52

Hospitals Prescription Filling Insurance 52

pharmaphorum

MAY 24, 2022

Organisations are missing out on the ability to harness their data to energise precision marketing and transform commercial performance. The pharma industry is adjusting to massive upheaval from the pandemic and markets are emerging from its grip reshaped and alive with competition. Single View of HCPs. Single View of HCPs.

Customer Service 110

Customer Service 110

pharmaphorum

OCTOBER 7, 2020

One of the noticeable effects of this has been a massive uptake of remote working across the industry, which has accentuated difficulties in conducting remote sales engagements due to poor customer data quality. It’s almost impossible to get a single, comprehensive view and an actionable view of their customer.

Pharmaceutical Companies 144

Pharmaceutical Companies Pharmaceutical Companies Hospitals 144

pharmaphorum

DECEMBER 29, 2022

The turbulence of the last three years can make it seem as though pharma manufacturers have been operating in an atmosphere of non-stop crisis. COVID-19 erupted, mutated, and was supplemented by the challenges of monkeypox and the need to catch up with major treatment and immunisation backlogs accumulated during the pandemic.

Vaccines 110

Vaccines 110

pharmaphorum

DECEMBER 28, 2022

In turn, the acquiring company will help the novel drugs navigate the complexities and costs of regulations and benefit from market access and economies of scale. Conducting internal pre-sale checks and looking at your level of compliance and licenses is a vital exercise. Looking beyond balance sheets. About the author.

Documentation 118

Documentation Pharmaceutical Companies Pharmaceutical Companies FDA 118

pharmaphorum

DECEMBER 12, 2022

The demand for high-calibre, sharply-focussed clinical knowledge and data is increasing as HCPs streamline and recalibrate their engagements with the pharmaceutical sector.

Communication 104

Communication 104

pharmaphorum

DECEMBER 23, 2022

A unified view of the HCP will emerge from clinical to commercial. Rarely are organisations able to view HCP relationships holistically – across clinical, medical, and sales – or reap the benefits of creating a unified understanding of the customer. Incentive compensation models will reward the right omnichannel behaviours.

Patient Care 105

Patient Care 105

pharmaphorum

DECEMBER 15, 2022

Within the life sciences space, traditional ways of leveraging social media include marketing and spreading awareness of a disease or treatment. Healthcare Provider (HCP) marketing. Still, many pharma and medical marketers have been reluctant to engage with HCPs on social media. Direct-to-Consumer (DTC) marketing.

Communication 103

Communication Vaccines FDA 103

pharmaphorum

JANUARY 25, 2023

Life sciences marketing has rapidly evolved to mirror that of consumer retail. It may not be surprising that the key to customer engagement optimisation, like many other processes within life sciences operations, is orchestrated data management and analysis. or “What is the next best engagement that my customers prefer to have?”

Communication 98

Communication 98

pharmaphorum

JANUARY 6, 2023

With the US economy teetering on a recession, sales and marketing budgets are expected to take a hit among businesses across sectors. The pharmaceutical industry is no exception. This investment of time and money is particularly important during a recession. Preventing patient drop-off.

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies 105

pharmaphorum

NOVEMBER 17, 2022

The DHSC said that this was an exceptional change, reflecting the rapid growth in sales in 2021 driven in part by COVID-19. According to the results of a calculator from Richard Williams, a market access consultant, the payment percentage could go over 30% in the final year of the current deal. Actual growth rate of measured sales.

98

98